- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01017926
Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption
April 4, 2016 updated by: Pfizer
An Open, Two Period, Two Treatment, Two Sequence, Crossed, Randomized, Single-Dose Study Of Two Oral Preparations Containing 0.25 Mg Of Triazolam (Halcion, Pharmacia & Upjohn S.A. De C.V. Vs. Product Made By Pfizer Pharmaceuticals LLC) In Healthy Volunteers Under Fasting Conditions
The purpose of this study is to compare the bioavailability of two oral formulations of Triazolam in healthy volunteers, in order to determine that they are bioequivalent.
Study Overview
Detailed Description
The bioequivalence trial of triazolam is due to change in manufacture site.
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Only healthy volunteers, between the ages of 18 and 40 years, will be included.
- Subjects' body mass index must be between 19-27.
- Volunteers must be in good health, as determined by the results of a complete clinical history prepared by doctors at the clinical research site and laboratory tests performed at certified clinical laboratories.
- Volunteers must agree to use at least two birth control methods (except hormonal contraceptives) from the first dose of the study drug and for up to 28 days after the last dose. (acceptable methods are surgically definitive sterilization, menopause, barrier methods such as condoms and diaphragm, and spermicidal gels/foams)
- The limits of variation permitted within normality at the screening visit will be: blood pressure (seated) 90 to 130 mm Hg systolic and 60 to 90 mm Hg diastolic, heart rate between 55 and 100 beats per minute and respiratory rate between 14 and 20 respirations per minute.
- The laboratory and cabinet tests required to include subjects in the studio will be: 1) Hematology: hemoglobin, hematocrit, total white blood cell count with differential, and platelet count, 2) 27-element blood chemistry, 3) Markers for hepatitis B and C. 4) Detection of HIV, 5) General urinalysis, 6) Drug abuse test in both study periods, 7) Qualitative pregnancy test in both study periods (if applicable) , 8) Electrocardiogram. (pre-screening/recruitment)
Exclusion Criteria:
- Subjects in whom any alteration is detected in their vital signs recorded at the screening of volunteers.
- Volunteers who fail to comply with the established criteria for inclusion.
- Volunteers with antecedents of cardiovascular, renal, hepatic, muscular, metabolic, and gastrointestinal disorders, including constipation; neurological, endocrine, and hematopoietic disorders; or any kind of anemia, asthma, mental illness, or other organic abnormalities, as well as those who have suffered a muscular traumatism within 21 days before the study.
- Volunteers who require any medication over the course of the study, aside from the drug being studied.
- Volunteers with antecedents of dyspepsia, gastritis, esophagitis, and duodenal or gastric ulcers.
- Volunteers who have been exposed to known hepatic enzyme inductors or inhibitors or have taken potentially toxic drugs within 30 days before the start of the study.
- Volunteers who have received any medication within 14 days or 5 half lives (whichever is longer) before the start of the study.
- Volunteers who have been hospitalized for any problem within seven months before the start of the study.
- Subjects who have received investigational drugs within 60 days prior to the study.
- Subjects allergic to any antibiotic and/or non-steroidal antiinflammatory analgesics.
- Subjects who have consumed alcohol or xanthine containing beverages (coffee, tea, cocoa, chocolate, mate, colas) or have consumed charcoal broiled foods or grapefruit juice within one week before the start of the study and until the last sample is taken.
- Subjects who have donated or lost 450 mL or more of blood within 60 days before the start of the study.
- History of regular consumption of alcohol exceeding 14 drinks/week (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of liquor within 6 months before the screening visit.
- Excessive use of products containing tobacco or nicotine, equivalent to 5 cigarettes per day.
- Female volunteers with positive results on the pregnancy test or in lactation.
- Volunteers who require a special diet for any reason, for example vegetarians.
- Disability of any kind that prevents the volunteer from understanding the nature, purpose, and potential consequences of the study.
- Evidence of an uncooperative attitude during the study.
- Female volunteers in lactation.
- Female volunteers who receive oral contraceptives
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Triazolam Reference Arm
There will be a clearance period of at least 3 days between the two phases of the study.
|
Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
|
Experimental: Triazolam Trial Arm
|
Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Establish Cmax, Tmax, elimination half life, area below the curve from zero to t, and area below the curve from zero to infinity (ABC 0-∞) of the two formulations of Triazolam in tablets
Time Frame: Day 1 and two after dosage is taken
|
Day 1 and two after dosage is taken
|
Statistically compare the bioavailability of the pharmaceutical formulations of Triazolam studied, to establish or rule out the existence of bioequivalence
Time Frame: Six to eight weeks after completing the study, a final report will be prepared.
|
Six to eight weeks after completing the study, a final report will be prepared.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Investigate the safety of both preparations based on the record of adverse events on completing both study periods
Time Frame: Up to 3 days after the 2nd period
|
Up to 3 days after the 2nd period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Primary Completion (Anticipated)
September 1, 2010
Study Completion (Anticipated)
September 1, 2010
Study Registration Dates
First Submitted
November 20, 2009
First Submitted That Met QC Criteria
November 20, 2009
First Posted (Estimate)
November 23, 2009
Study Record Updates
Last Update Posted (Estimate)
April 6, 2016
Last Update Submitted That Met QC Criteria
April 4, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A6781002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Triazolam
-
PfizerCompleted
-
TakedaCompletedDrug AbuseUnited States
-
Orphan MedicalJohns Hopkins UniversityCompleted
-
University of ManitobaRecruiting
-
University of PittsburghCompletedDental AnxietyUnited States
-
AcelRx Pharmaceuticals, Inc.Completed
-
National Institute on Drug Abuse (NIDA)CompletedCocaine-Related DisordersUnited States
-
Janssen Research & Development, LLCCompleted
-
Boston Medical CenterCompleted
-
Akili Interactive Labs, Inc.CompletedHealthyUnited States